Mindpeak Announces CE-mark For New Product: Breast HER2 RoI
(PresseBox) (Hamburg, ) Mindpeak announces the CE-mark for another new product: Mindpeak Breast HER2 RoI (Region of Interest) supports pathologists in the scoring of digital images of breast cancer tissue, which underwent immunohistochemical (IHC) staining of the human epidermal growth factor receptor 2 (HER2). The statistical evaluation shows that the agreement rate of nearly 79% when scoring assisted by Mindpeak Breast HER2 RoI is significantly larger than the clinical state-of-the-art agreement rate of 68% when scoring manually. Breast HER2 RoI is the 8th CE-marked product Mindpeak has launched into the market in the last 14 months.
„I am very pleased that with our new software we can make a contribution to breast cancer therapy. It is especially interesting as the Trastuzumab-Deruxtecan (Enhertu) therapy – has recently become available, where the distinction between “0” (negative) and “1+” (weakly positive = HER2low) is now important – something that pathologists were not used to distinguishing until now. Here, an AI that delivers reproducible results can support pathologists particularly well“, says Mindpeak’s CEO and founder Felix Faber.
Founded by Faber and Dr Tobias Lang, the company has been developing AI-software for pathologists since 2018. In doing so, Mindpeak has developed the first AI solution for digital pathology to make it into clinical routine in both Europe and the US. In partnership with international laboratories and leading pathology system providers, Mindpeak continues to expand its product range and develop it into an indispensable part of the digitized pathology workflow. This has made Mindpeak the most integrated company in this field globally.
SOURCE: PresseBox
